Lead Product(s): Desidustat
Therapeutic Area: Hematology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: China Medical System Holdings Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 20, 2020
Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.